(Reuters) – Eli Lilly (NYSE:) missed Wall Street estimates for third-quarter profit on Wednesday, even as demand for its weight-loss drug soared, hurt by higher manufacturing and acquisition-related costs.
The company earned $1.18 per share on an adjusted basis for the quarter ended Sept.30, compared with analysts’ average estimate of $1.47, according to LSEG data.